Using real-world data to predict findings of an ongoing phase IV trial: glycemic control of semaglutide versus standard of care
{{output}}
Objective: Using national claims databases, we sought to emulate the design of the ongoing SEPRA trial and predict its findings, comparing the effects of once weekly semaglutide to SoC medications on glycemic control (A1C
